Beta-secretase

Structure, function, and evolution

Chitra Venugopal, Christina M. Demos, K. S. Jagannatha Rao, Miguel Pappolla, Kumar Sambamurti

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

The most popular current hypothesis is that Alzheimer's disease (AD) is caused by aggregates of the amyloid peptide (Aβ), which is generated by cleavage of the Aβ protein precursor (APP) by β-secretase (BACE-1) followed by γ-secretase. BACE-1 cleavage is limiting for the production of Aβ, making it a particularly good drug target for the generation of inhibitors that lower Aβ. A landmark discovery in AD was the identification of BACE-1 (a.k.a. Memapsin-2) as a novel class of type I transmembrane aspartic protease. Although BACE-2, a homologue of BACE-1, was quickly identified, follow up studies using knockout mice demonstrated that BACE-1 was necessary and sufficient for most neuronal Aβ generation. Despite the importance of BACE-1 as a drug target, development has been slow due to the incomplete understanding of its function and regulation and the difficulties in developing a brain penetrant drug that can specifically block its large catalytic pocket. This review summarizes the biological properties of BACE-1 and attempts to use phylogenetic perspectives to understand its function. The article also addresses the challenges in discovering a selective drug-like molecule targeting novel mechanisms of BACE-1 regulation.

Original languageEnglish
Pages (from-to)278-294
Number of pages17
JournalCNS and Neurological Disorders - Drug Targets
Volume7
Issue number3
DOIs
StatePublished - Jun 2008
Externally publishedYes

Fingerprint

Amyloid Precursor Protein Secretases
Pharmaceutical Preparations
Alzheimer Disease
Protein Precursors
Amyloid
Knockout Mice
Peptide Hydrolases
Brain

Keywords

  • Alzheimer
  • Amyloid
  • Aspartyl protease
  • BACE-1
  • Memapsin
  • Secretase

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology

Cite this

Beta-secretase : Structure, function, and evolution. / Venugopal, Chitra; Demos, Christina M.; Jagannatha Rao, K. S.; Pappolla, Miguel; Sambamurti, Kumar.

In: CNS and Neurological Disorders - Drug Targets, Vol. 7, No. 3, 06.2008, p. 278-294.

Research output: Contribution to journalArticle

Venugopal, C, Demos, CM, Jagannatha Rao, KS, Pappolla, M & Sambamurti, K 2008, 'Beta-secretase: Structure, function, and evolution', CNS and Neurological Disorders - Drug Targets, vol. 7, no. 3, pp. 278-294. https://doi.org/10.2174/187152708784936626
Venugopal, Chitra ; Demos, Christina M. ; Jagannatha Rao, K. S. ; Pappolla, Miguel ; Sambamurti, Kumar. / Beta-secretase : Structure, function, and evolution. In: CNS and Neurological Disorders - Drug Targets. 2008 ; Vol. 7, No. 3. pp. 278-294.
@article{aaaed0104b62479db358303409686d7d,
title = "Beta-secretase: Structure, function, and evolution",
abstract = "The most popular current hypothesis is that Alzheimer's disease (AD) is caused by aggregates of the amyloid peptide (Aβ), which is generated by cleavage of the Aβ protein precursor (APP) by β-secretase (BACE-1) followed by γ-secretase. BACE-1 cleavage is limiting for the production of Aβ, making it a particularly good drug target for the generation of inhibitors that lower Aβ. A landmark discovery in AD was the identification of BACE-1 (a.k.a. Memapsin-2) as a novel class of type I transmembrane aspartic protease. Although BACE-2, a homologue of BACE-1, was quickly identified, follow up studies using knockout mice demonstrated that BACE-1 was necessary and sufficient for most neuronal Aβ generation. Despite the importance of BACE-1 as a drug target, development has been slow due to the incomplete understanding of its function and regulation and the difficulties in developing a brain penetrant drug that can specifically block its large catalytic pocket. This review summarizes the biological properties of BACE-1 and attempts to use phylogenetic perspectives to understand its function. The article also addresses the challenges in discovering a selective drug-like molecule targeting novel mechanisms of BACE-1 regulation.",
keywords = "Alzheimer, Amyloid, Aspartyl protease, BACE-1, Memapsin, Secretase",
author = "Chitra Venugopal and Demos, {Christina M.} and {Jagannatha Rao}, {K. S.} and Miguel Pappolla and Kumar Sambamurti",
year = "2008",
month = "6",
doi = "10.2174/187152708784936626",
language = "English",
volume = "7",
pages = "278--294",
journal = "CNS and Neurological Disorders - Drug Targets",
issn = "1871-5273",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Beta-secretase

T2 - Structure, function, and evolution

AU - Venugopal, Chitra

AU - Demos, Christina M.

AU - Jagannatha Rao, K. S.

AU - Pappolla, Miguel

AU - Sambamurti, Kumar

PY - 2008/6

Y1 - 2008/6

N2 - The most popular current hypothesis is that Alzheimer's disease (AD) is caused by aggregates of the amyloid peptide (Aβ), which is generated by cleavage of the Aβ protein precursor (APP) by β-secretase (BACE-1) followed by γ-secretase. BACE-1 cleavage is limiting for the production of Aβ, making it a particularly good drug target for the generation of inhibitors that lower Aβ. A landmark discovery in AD was the identification of BACE-1 (a.k.a. Memapsin-2) as a novel class of type I transmembrane aspartic protease. Although BACE-2, a homologue of BACE-1, was quickly identified, follow up studies using knockout mice demonstrated that BACE-1 was necessary and sufficient for most neuronal Aβ generation. Despite the importance of BACE-1 as a drug target, development has been slow due to the incomplete understanding of its function and regulation and the difficulties in developing a brain penetrant drug that can specifically block its large catalytic pocket. This review summarizes the biological properties of BACE-1 and attempts to use phylogenetic perspectives to understand its function. The article also addresses the challenges in discovering a selective drug-like molecule targeting novel mechanisms of BACE-1 regulation.

AB - The most popular current hypothesis is that Alzheimer's disease (AD) is caused by aggregates of the amyloid peptide (Aβ), which is generated by cleavage of the Aβ protein precursor (APP) by β-secretase (BACE-1) followed by γ-secretase. BACE-1 cleavage is limiting for the production of Aβ, making it a particularly good drug target for the generation of inhibitors that lower Aβ. A landmark discovery in AD was the identification of BACE-1 (a.k.a. Memapsin-2) as a novel class of type I transmembrane aspartic protease. Although BACE-2, a homologue of BACE-1, was quickly identified, follow up studies using knockout mice demonstrated that BACE-1 was necessary and sufficient for most neuronal Aβ generation. Despite the importance of BACE-1 as a drug target, development has been slow due to the incomplete understanding of its function and regulation and the difficulties in developing a brain penetrant drug that can specifically block its large catalytic pocket. This review summarizes the biological properties of BACE-1 and attempts to use phylogenetic perspectives to understand its function. The article also addresses the challenges in discovering a selective drug-like molecule targeting novel mechanisms of BACE-1 regulation.

KW - Alzheimer

KW - Amyloid

KW - Aspartyl protease

KW - BACE-1

KW - Memapsin

KW - Secretase

UR - http://www.scopus.com/inward/record.url?scp=48249093460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48249093460&partnerID=8YFLogxK

U2 - 10.2174/187152708784936626

DO - 10.2174/187152708784936626

M3 - Article

VL - 7

SP - 278

EP - 294

JO - CNS and Neurological Disorders - Drug Targets

JF - CNS and Neurological Disorders - Drug Targets

SN - 1871-5273

IS - 3

ER -